These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
271 related articles for article (PubMed ID: 29895386)
1. Prebiopsy biparametric MRI: differences of PI-RADS version 2 in patients with different PSA levels. Choi MH; Lee YJ; Jung SE; Rha SE; Byun JY Clin Radiol; 2018 Sep; 73(9):810-817. PubMed ID: 29895386 [TBL] [Abstract][Full Text] [Related]
2. MRI combined with PSA density in detecting clinically significant prostate cancer in patients with PSA serum levels of 4∼10ng/mL: Biparametric versus multiparametric MRI. Han C; Liu S; Qin XB; Ma S; Zhu LN; Wang XY Diagn Interv Imaging; 2020 Apr; 101(4):235-244. PubMed ID: 32063483 [TBL] [Abstract][Full Text] [Related]
3. Can the addition of clinical information improve the accuracy of PI-RADS version 2 for the diagnosis of clinically significant prostate cancer in positive MRI? Polanec SH; Bickel H; Wengert GJ; Arnoldner M; Clauser P; Susani M; Shariat SF; Pinker K; Helbich TH; Baltzer PAT Clin Radiol; 2020 Feb; 75(2):157.e1-157.e7. PubMed ID: 31690449 [TBL] [Abstract][Full Text] [Related]
4. Comparison of Cancer Detection Rates Between TRUS-Guided Biopsy and MRI-Targeted Biopsy According to PSA Level in Biopsy-Naive Patients: A Propensity Score Matching Analysis. Choi YH; Kang MY; Sung HH; Jeon HG; Chang Jeong B; Seo SI; Jeon SS; Kim CK; Park BK; Lee HM Clin Genitourin Cancer; 2019 Feb; 17(1):e19-e25. PubMed ID: 30415878 [TBL] [Abstract][Full Text] [Related]
5. Head-to-head comparison of biparametric versus multiparametric MRI of the prostate before robot-assisted transperineal fusion prostate biopsy. Thaiss WM; Moser S; Hepp T; Kruck S; Rausch S; Scharpf M; Nikolaou K; Stenzl A; Bedke J; Kaufmann S World J Urol; 2022 Oct; 40(10):2431-2438. PubMed ID: 35922717 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Biparametric and Multiparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2.1. Tamada T; Kido A; Yamamoto A; Takeuchi M; Miyaji Y; Moriya T; Sone T J Magn Reson Imaging; 2021 Jan; 53(1):283-291. PubMed ID: 32614123 [TBL] [Abstract][Full Text] [Related]
7. Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING). Wetterauer C; Matthias M; Pueschel H; Deckart A; Bubendorf L; Mortezavi A; Arbelaez E; Jean Winkel D; Heye T; Boll DT; Merkle E; Hayoz S; Seifert HH; Rentsch CA Eur Urol Focus; 2024 Mar; 10(2):332-338. PubMed ID: 38402105 [TBL] [Abstract][Full Text] [Related]
8. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. Stabile A; Dell'Oglio P; De Cobelli F; Esposito A; Gandaglia G; Fossati N; Brembilla G; Cristel G; Cardone G; Deho' F; Losa A; Suardi N; Gaboardi F; Del Maschio A; Montorsi F; Briganti A Eur Urol Oncol; 2018 May; 1(1):29-36. PubMed ID: 31100225 [TBL] [Abstract][Full Text] [Related]
9. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative. Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021 [TBL] [Abstract][Full Text] [Related]
10. Biparametric Magnetic Resonance Imaging-Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index Lesion. Kim MJ; Park SY J Magn Reson Imaging; 2022 Apr; 55(4):1226-1233. PubMed ID: 34296803 [TBL] [Abstract][Full Text] [Related]
11. Clinically Significant Prostate Cancer Detection After a Negative Prebiopsy MRI Examination: Comparison of Biparametric Versus Multiparametric MRI. Gan JM; Kikano EG; Smith DA; Rao S; Podury R; Wang M; Durieux JC; Paspulati RM; Ponsky L; Ramaiya NH; Tirumani SH AJR Am J Roentgenol; 2022 May; 218(5):859-866. PubMed ID: 34817189 [No Abstract] [Full Text] [Related]
12. Retrospective comparison of direct in-bore magnetic resonance imaging (MRI)-guided biopsy and fusion-guided biopsy in patients with MRI lesions which are likely or highly likely to be clinically significant prostate cancer. Venderink W; van der Leest M; van Luijtelaar A; van de Ven WJM; Fütterer JJ; Sedelaar JPM; Huisman HJ World J Urol; 2017 Dec; 35(12):1849-1855. PubMed ID: 28871396 [TBL] [Abstract][Full Text] [Related]
13. Analysis of risk factors for determining the need for prostate biopsy in patients with negative MRI. Liang L; Qi F; Cheng Y; Zhang L; Cao D; Cheng G; Hua L Sci Rep; 2021 Mar; 11(1):6048. PubMed ID: 33723287 [TBL] [Abstract][Full Text] [Related]
14. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region. Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557 [TBL] [Abstract][Full Text] [Related]
15. Prebiopsy Biparametric MRI for Clinically Significant Prostate Cancer Detection With PI-RADS Version 2: A Multicenter Study. Choi MH; Kim CK; Lee YJ; Jung SE AJR Am J Roentgenol; 2019 Apr; 212(4):839-846. PubMed ID: 30779662 [TBL] [Abstract][Full Text] [Related]
16. [Analysis of the relationship between PI-RADS scores and the pathological results of targeted biopsy based on MRI]. Wang YM; Shang JW; Dong L; Liang LH; Zhao RZ; Liang C; Wang SQ; Xia W; Cheng G; Hua LX Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):942-947. PubMed ID: 37968079 [No Abstract] [Full Text] [Related]
17. Magnetic Resonance Imaging (MRI)-Targeted Biopsy in Patients with Prostate-Specific Antigen (PSA) Levels <20 ng/mL: A Single-Center Study in Northeastern China. Dai Z; Liu Y; Huangfu Z; Wang L; Liu Z Med Sci Monit; 2021 Aug; 27():e930234. PubMed ID: 34365459 [TBL] [Abstract][Full Text] [Related]
18. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3? Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884 [TBL] [Abstract][Full Text] [Related]
19. Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer. Alberts AR; Roobol MJ; Drost FH; van Leenders GJ; Bokhorst LP; Bangma CH; Schoots IG BJU Int; 2017 Oct; 120(4):511-519. PubMed ID: 28267899 [TBL] [Abstract][Full Text] [Related]
20. Diagnostic Accuracy and Value of Magnetic Resonance Imaging-Ultrasound Fusion Transperineal Targeted and Template Systematic Prostate Biopsy Based on Bi-parametric Magnetic Resonance Imaging. Noh TI; Tae JH; Kim HK; Shim JS; Kang SG; Sung DJ; Cheon J; Lee JG; Kang SH Cancer Res Treat; 2020 Jul; 52(3):714-721. PubMed ID: 32054151 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]